Please ensure Javascript is enabled for purposes of website accessibility

Why Editas Medicine Is Crashing Today

By Keith Speights – Updated Apr 21, 2019 at 11:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CRISPR-focused biotech stock plunged following the surprising resignation of its CEO.

What happened

Shares of Editas Medicine (EDIT 0.81%) have crashed 21.2% as of 11:09 a.m. EST on Tuesday. The biotech has announced the unexpected departure of CEO Katrine Bosley, who had led Editas since 2014. Editas Medicine's press release stated that Bosley will step down as president and CEO effective March 1, 2019. Bosley also resigned from Editas' board of directors. 

So what

Whenever there's a sudden departure of a top executive, it raises questions about what could be going on with a company. That's especially the case for Editas Medicine, since CFO Andrew Hack also left in December to join Bain Capital. 

Section of DNA breaking away

Image source: Getty Images.

Editas didn't provide any details of Bosley's exit as CEO. Bosley tweeted Tuesday morning that leaving Editas "was a tough decision" but didn't say why she is stepping down. 

Just a few weeks ago, Bosley stated at the J. P. Morgan Healthcare Conference that it was "an incredibly exciting time" for Editas. She sounded optimistic about the biotech's prospects and gave no hints that she would soon be leaving the company. 

At this point, there's simply no way to know for sure why Bosley left. It's possible that the underlying reasons behind her resignation (and potentially Hack's exit as CFO also) could change the investing thesis for Editas Medicine. However, it's also possible that the departures of these top executives have nothing to do with the long-term prospects for the biotech.

Now what

Editas Medicine appointed Cynthia Collins as interim CEO. Collins is a member of the company's board of directors and has an impressive resume in the healthcare industry. Editas has initiated a search for a permanent replacement for Bosley. 

The biotech also continues to advance its lead pipeline candidate, EDIT-101. Editas expects to screen patients in the first half of this year for a phase 1/2 clinical study evaluating the CRISPR gene editing therapy in treating Leber congenital amaurosis type 10 (LCA10), the leading genetic cause of childhood blindness.  

Investors who already own Editas stock probably should do nothing for now, despite the questions raised by Bosley's departure. On the other hand, investors considering buying Editas might want to hold off until the dust settles.

Check out the latest Editas earnings call transcript.

Keith Speights owns shares of Editas Medicine. The Motley Fool owns shares of and recommends Editas Medicine. The Motley Fool has a disclosure policy.

Stocks Mentioned

Editas Medicine Stock Quote
Editas Medicine
$9.98 (0.81%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.